Activating mutations of the stem cell factor receptor tyrosine kinase (c-Kit) or platelet-derived growth factor receptor α (PDGFRA) can be found in at least 85% of cases of gastrointestinal stromal tumors. The therapeutic options include surgery, local treatment and systemic treatment with tyrosine kinase inhibitors, such as imatinib or sunitinib. Kinase inhibitor-based treatment is used in neoadjuvant, adjuvant and metastatic settings. Knowledge of the individual mutational status allows prediction of response to first-line medical treatment and provides information which can guide selection of the appropriate second-line therapy.
|Translated title of the contribution||Mutational status based therapy algorithm for gastrointestinal stroma tumors. Does c-Kit/PDGFRA mutational analysis affect treatment decisions?|
|Number of pages||7|
|Publication status||Published - 01.2012|